Interrogating alpha-synuclein aggregate-associated proteomes to identify modifiers of lewy body disease. - 1. Abstract after alzheimer's disease, lewy body dementia is the most common form of dementia…

Active Grant Awarded

Award ID
RF1NS147442
Recipient
Awarding agency
Obligated
$1,878,189

Award facts

Completion date 7% complete
Place of performance
Jacksonville, FL 32224, USA

Award details come from USAspending.gov.

About this award

The Department of Health and Human Services, National Institutes of Health, National Institute of Neurological Disorders and Stroke awarded Mayo Clinic Jacksonville (A Nonprofit Corporation) $1.878 million on September 3, 2026, under Grant RF1NS147442 in the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853). The period of performance ends August 31, 2029, and the full amount is obligated.

The project, titled "Interrogating alpha-synuclein aggregate-associated proteomes to identify modifiers of Lewy body disease," seeks molecular cofactors that drive alpha-synuclein aggregation and neurodegeneration in Lewy body dementia. Aim 1 applies proximity-dependent biotin identification (BioID) in human iPSC-derived neurons and glia and in murine organotypic brain slice cultures, exposed either to soluble alpha-synuclein or to insoluble aggregates induced by human-derived proteopathic seeds. Aim 2 applies in situ probe-dependent proximity profiling (PROPPR) in fixed human postmortem brain tissue across dementia with Lewy bodies, Parkinson disease, and multiple system atrophy, comparing samples over time. Biotinylated proteins are isolated by affinity purification and identified by quantitative mass spectrometry.

Place of performance is Jacksonville, Florida 32224.

The program funds extramural NINDS research into the fundamental structure and function of the brain and nervous system, and into the reduction of neurological disease burden.

Description

Interrogating alpha-synuclein aggregate-associated proteomes to identify modifiers of lewy body disease. - 1. Abstract after alzheimer's disease, lewy body dementia is the most common form of dementia afflicting aging individuals. The goal of this project is to advance our mechanistic understanding of the role that alpha-synuclein plays in disease pathogenesis and progression of alzheimer disease related dementias (ADRDS) such as lewy body dementia (LBD) by discovering molecular interactors of alpha-synuclein and defining the alpha-synuclein aggregate-associated interactome. We hypothesize that the cellular and molecular environment contributes to αsyn-associated lewy pathology processes and that quantitative proteomics can be applied to capture the molecular microenvironment proximal to αsyn as IT forms oligomers, protofibrils, and insoluble aggregates to reveal key cofactors in aggregation and neurodegeneration processes. In this application we will employ proximity-dependent biotin identification in live human neurons and mouse brain slices (BIOID) (aim 1) and in situ probe-dependent proximity profiling in fixed human patient brain tissue (PROPPR) (aim 2) to enable biotinylation of αsyn-associated cofactors under physiological and pathogenic conditions. Proximal biotinylated proteins will be isolated via affinity purification and identified by quantitative mass spectrometry. We propose the following coordinated aims to accomplish this goal: in aim 1 we will capture, identify, and differentiate intracellular proteins in proximity to soluble alpha-synuclein in vitro in human ipsc-derived neurons and glia and EX vivo in murine organotypic brain slice cultures, or in proximity to insoluble aggregates of alpha- synuclein induced by human-derived proteopathic seeds. In aim 2 we will use in situ probe-dependent proximity profiling in human postmortem brain to probe the αsyn-associated proteome in different synucleinopathies (DLB, PD, MSA), over time (comparing brain regions affected early versus late in disease course), and with consideration of comorbid pathologies (TAU, TDP-43, beta-amyloid) to reveal the underlying global and local proteomic landscape of synucleinopathies and shed light on the molecular heterogeneity and mechanisms underlying disease. Finally in aim 3 we will functionally investigate the pathophysiological role of select candidate proteins in human tissue, cell models, EX vivo brain slice cultures or in vivo in murine models. Successful completion of these aims will specifically identify molecular cofactors of αsyn monomers, oligomers, and aggregates and determine the processes at play during lewy pathology formation, maturation, and progression.

Quick answers

Who received award RF1NS147442?

RF1NS147442 was awarded to Mayo Clinic Jacksonville (A Nonprofit Corporation) by National Institute of Neurological Disorders and Stroke (National Institutes of Health) on September 3, 2026.

How much is award RF1NS147442 worth?

$1,878,189 has been obligated on RF1NS147442.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award